Rocket Pharmaceuticals (RCKT) Capital Leases (2020 - 2026)

Rocket Pharmaceuticals (RCKT) has 7 years of Capital Leases data on file, last reported at $19.3 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Leases changed 0.18% year-over-year to $19.3 million; the trailing twelve-month figure through Mar 2026 stood at $19.3 million (changed 0.18% YoY), and the FY2025 full-year result was $19.4 million, changed 0.11% from the prior year.
• Capital Leases held at $19.3 million in Q1 2026, from $19.4 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $19.4 million in Q4 2024 to a low of $19.2 million in Q1 2022.
• A 5-year average of $19.3 million and a median of $19.4 million in 2023 frame the typical range for Capital Leases.
• Across the five-year window, Capital Leases increased 0.78% in 2022 and retreated 0.18% in 2026, its largest moves.
• Tracing RCKT's Capital Leases over 5 years: stood at $19.3 million in 2022, then advanced by 0.44% to $19.4 million in 2023, then climbed by 0.16% to $19.4 million in 2024, then fell by 0.11% to $19.4 million in 2025, then declined by 0.08% to $19.3 million in 2026.
• Business Quant data shows RCKT's Capital Leases at $19.3 million in Q1 2026, $19.4 million in Q4 2025, and $19.4 million in Q3 2025.